Custom breast shell could make radiation therapy faster and more comfortable
NCT ID NCT07711847
First seen Jul 17, 2026 · Last updated Jul 17, 2026
Summary
This trial tests whether a custom-made breast holder called VENUS SHELL™ can improve positioning and comfort during radiotherapy for early-stage breast cancer. Participants lie on their stomach while the device holds the breast in place, aiming to deliver precise radiation in shorter sessions. The study enrolls women aged 40 and older who have had breast-conserving surgery and need radiotherapy.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- a personalized breast holder called VENUS SHELL™ used during radiotherapy
- What this could lead to
- If successful, this device could make radiotherapy faster, more accurate, and more comfortable for women with early-stage breast cancer.
- What could go wrong
- This is a small early-stage study focused on feasibility and safety, so the device may not prove beneficial or practical in routine care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 30 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Jul 2026
An estimate. Start dates often move.
- Expected to finish
-
Jul 2027
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
40 years and older
- Sex
-
Female participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
INCLUSION Criteria: * Written informed consent according to ICH/GCP regulations before registration and prior to any study-specific procedures * Upfront breast conservative surgery * Radiotherapy planned within 12 weeks after surgery * ECOG/WHO performance status ≤2 * Age ≥40 year For invasive breast cancer only: * Staging pT1-T2, N0M0 (Tumor size ≤3 cm) * If no sentinel lymph node biopsy performed, patient must be clinically N0 * Negative margins (no tumor on ink) For ductal carcinoma in situ only: * Staging pTis (tumor size ≤3 cm) * Negative margins (≥2 mm) EXCLUSION Criteria: * Patient of male sex * Inability to obtain informed consent or adhere to the CIP * Breast skin damage that could prevent VENUS SHELL™ usage according to protocol timeline (e.g. presence of any skin or soft tissue wound that failed to show evidence of progression towards healing, clinical signs of active infection at or immediately adjacent to the intended intervention site, etc.) * Known germline BRCA1/2 mutation * Unable to lay prone * Unable to undergo imaging by CT scan * Documented hypersensitivity or allergy to medical plasters, acrylonitrile butadiene styrene * Any serious underlying medical, psychiatric, psychological, familial or geographical condition, which in the judgment of the investigator may affect patient compliance or place the patient at high risk within the study. * Pregnancy or breast feeding * Claustrophobia * Patient with a body weight exceeding 120 kg * Patient with pendulous breasts that come into contact with the CT table, preventing adequate space for shell usage * Presence of any cardiac implantable electronic device (CIED), including but not limited to a pacemaker, implantable cardioverter-defibrillator (ICD), cardiac resynchronization therapy (CRT) device, or other electronically active implant.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Ductal carcinoma in situ, dcis are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The study's own enquiry address
This study publishes an address for enquiries. See it below .
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
NYU Grossman School of Medicine
RECRUITINGNew York, New York, 10016, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.